GRDN Relative Valuation
GRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GRDN is overvalued; if below, it's undervalued.
Historical Valuation
Guardian Pharmacy Services Inc (GRDN) is now in the Fair zone, suggesting that its current forward PE ratio of 22.05 is considered Fairly compared with the five-year average of 24.28. The fair price of Guardian Pharmacy Services Inc (GRDN) is between 18.25 to 21.95 according to relative valuation methord.
Relative Value
Fair Zone
18.25-21.95
Current Price：20.40
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
8.45
P/B
Median3y
8.58
Median5y
8.58
3.59
FCF Yield
Median3y
3.18
Median5y
3.18
Competitors Valuation Multiple
The average P/S ratio for GRDN's competitors is 0.32, providing a benchmark for relative valuation. Guardian Pharmacy Services Inc Corp (GRDN) exhibits a P/S ratio of 1.00, which is 212.60% above the industry average. Given its robust revenue growth of 19.57%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Guardian Pharmacy Services Inc (GRDN) currently overvalued or undervalued?
What is Guardian Pharmacy Services Inc (GRDN) fair value?
How does GRDN's valuation metrics compare to the industry average?
What is the current P/B ratio for Guardian Pharmacy Services Inc (GRDN) as of Jul 13 2025?
What is the current FCF Yield for Guardian Pharmacy Services Inc (GRDN) as of Jul 13 2025?
What is the current Forward P/E ratio for Guardian Pharmacy Services Inc (GRDN) as of Jul 13 2025?